ACIU - AC Immune SA
| Previous Close | 4.7200 |
| Open | 4.7300 |
| Bid | 4.1500 x 1200 |
| Ask | 4.9500 x 800 |
| Day's Range | 4.5800 - 4.8000 |
| 52 Week Range | 3.2500 - 17.4000 |
| Volume | 125,193 |
| Avg. Volume | 667,987 |
| Market Cap | 321.597M |
| Beta (3Y Monthly) | 0.03 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.5470 |
| Earnings Date | May 1, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.86 |
- Simply Wall St.•14 days ago
What Percentage Of AC Immune SA (NASDAQ:ACIU) Shares Do Insiders Own?
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! If you want to know who really controls AC Immune SA (NASDAQ:ACIU), then you'll have to look at the makeup of its share regis...
- Zacks•20 days ago
Alector (ALEC) Initiates Phase I Alzheimer's Study on AL003
Alector, Inc. (ALEC) initiates the phase I INTERCEPT study on AL003 for the treatment of Alzheimer???s disease.
- GlobeNewswire•22 days ago
AC Immune to Present at the H.C. Wainwright Global Life Sciences Conference
LAUSANNE, Switzerland, April 01, 2019 -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative.
- GlobeNewswire•25 days ago
AC Immune Presents New Data on Alpha-Synuclein PET Tracer at AD/PD™ Conference
Demonstrated high-affinity binding to human Parkinson’s disease-brain derived alpha-synucleinPotentially first diagnostic for detecting and monitoring Parkinson’s diseaseFurther.
- Zacks•27 days ago
Lilly (LLY) Signs New Immunology Deal With Private Biotech
Eli Lilly (LLY) gets an exclusive, worldwide license to develop and commercialize a novel immunometabolism target from private biotech, ImmuNext.
- GlobeNewswire•27 days ago
New Clinical Data on AC Immune’s Novel Next Generation Tau PET-Tracer Presented by Licensing Partner, Life Molecular Imaging, at AD/PD™ Conference
Next generation Tau PET-Tracer, 18F-PI-2620, offers opportunities to diagnose and monitor tauopathies, including AD and PSP New data further support 18F-PI-2620’s potential as.
- Zacks•28 days ago
What Makes AC Immune (ACIU) a New Buy Stock
AC Immune (ACIU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
- GlobeNewswire•last month
AC Immune Reports Full-Year 2018 Financial Results and Provides Business Update
CHF 300 million cash position as of Q1 2019 funds operations through Q3 2023 Eli Lilly deal validates MorphomerTM platform Initiation of second Phase 2 trial of Tau antibody.
- GlobeNewswire•2 months ago
AC Immune to Report Progress of Early-Stage Pipeline at AD/PD™ Congress
LAUSANNE, Switzerland, March 04, 2019 -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative.
- Zacks•2 months ago
Will Difficult Comparison Hurt Bio-Rad's (BIO) Q4 Earnings?
Bio-Rad (BIO) apprehends a year-over-year decline in revenues within Life Sciences segment due to difficult comparison.
- Zacks•2 months ago
Will Hospice Strength Show on Amedisys' (AMED) Q4 Earnings?
An increased reimbursement of approximately $1 million has boosted Amedisys' (AMED) Hospice business.
- Zacks•2 months ago
What's in Store for Tandem Diabetes' (TNDM) Q4 Earnings?
Strong domestic sales along with the launch of the t:slim X2 Insulin Pump in select international markets are likely to drive Tandem Diabetes' (TNDM) Q4 earnings.
- GlobeNewswire•2 months ago
AC Immune Announces Anti-Tau Monoclonal Antibody Entering Second Phase 2 Trial in Moderate Alzheimer’s Disease
Study complements ongoing trial in the prodromal to mild population LAUSANNE, Switzerland, Feb. 20, 2019 -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage.
- GlobeNewswire•2 months ago
AC Immune Makes Two Appointments to Executive Committee to Accelerate Product Development
LAUSANNE, Switzerland, Feb. 07, 2019 -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative.
- Zacks•3 months ago
AC Immune Enters Oversold Territory
AC Immune SA (ACIU) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
- Market Realist•3 months ago
Why AC Immune SA Stock Crashed on January 30
Why Did AC Immune SA Stock Crash on January 30?Share price movementsOn January 30, AC Immune SA (ACIU) issued a press release announcing the discontinuation of Phase 3 trials, CREAD 1 and CREAD 2, by Roche Holdings (RHHBY). The decision was based on
- Zacks•3 months ago
Roche Halts Two Late-Stage Studies on Alzheimer's Candidate
Roche (RHHBY) discontinues two phase III studies evaluating its anti-beta-amyloid molecule, crenezumab in people with early sporadic Alzheimer's disease.
- Investor's Business Daily•3 months ago
Roche Scraps Alzheimer's Test — But Investors Punished This Stock
Biogen stock slipped Wednesday after Roche and AC Immune opted to scrap two Alzheimer's treatment studies — leading investors to look for details of Biogen's own experimental drug.
Reuters•3 months agoRoche, AC Immune drop Alzheimer drug trials after setback
Roche Holding and partner AC Immune SA called a halt to two late-stage clinical trials of their crenezumab drug for early Alzheimer's, the latest in a string of failures to find a treatment for the progressive brain disease. The announcement from Roche and its Swiss-based partner AC Immune came after an interim analysis indicated it was unlikely to be effective, the Swiss drugmaker said on Wednesday. Alzheimer's, a fatal disease which affects memory and language as it progresses, is a compelling target for drugmakers as the numbers affected across the globe swell with an ageing population, but experimental Alzheimer's drugs have had a dismal track record, with more than 100 failures.
- Motley Fool•3 months ago
Why AC Immune SA Is Imploding
Shares crater after the company provides investors with terrible clinical news.
- American City Business Journals•3 months ago
Genentech kills big drug study in early Alzheimer's patients
Genentech's Alzheimer's-fighting drug failed two late-stage studies, but other Bay Area companies are continuing with different approaches to the memory-stealing disease.
- Reuters•3 months ago
Roche drops Alzheimer drug trials after setback
Roche Holding will halt two late-stage clinical trials of its crenezumab drug in early Alzheimer's disease after an interim analysis indicated it was unlikely to hits its primary goal, the Swiss drugmaker said on Wednesday. Roche was working on the product with AC Immune.
- GlobeNewswire•3 months ago
AC Immune Reports Discontinuation of Phase III CREAD 1 and 2 Studies of Crenezumab in Alzheimer’s Disease
AC Immune SA (ACIU) announced today that Roche, the parent company of its collaboration partner, is discontinuing the CREAD 1 and CREAD 2 (BN29552 and BN29553) Phase III studies of the investigational anti-beta-amyloid molecule, crenezumab, in people with prodromal to mild sporadic Alzheimer’s disease (AD). The decision came after an interim analysis conducted by the Independent Data Monitoring Committee (IDMC).
- Zacks•3 months ago
Top Ranked Momentum Stocks to Buy for January 25th
Top Ranked Momentum Stocks to Buy for January 25th
